Last reviewed · How we verify
Meditoxin
At a glance
| Generic name | Meditoxin |
|---|---|
| Also known as | Neuronox® |
| Sponsor | Seoul National University Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Long-term Safety and Efficacy of MEDITOXIN® in Treatment Glabellar Lines (PHASE4)
- Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Subject With Idiopathic Overactive Bladder (PHASE3)
- MEDITOXIN® Treatment in Subject With Benign Masseteric Hypertrophy (PHASE3)
- Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Primary Axillary Hyperhidrosis (PHASE3)
- MEDITOXIN® Treatment in Subjects With Post-Stroke Upper Limb Spasticity (PHASE4)
- Efficacy and Safety of MEDITOXIN® in Cervical Dystonia (PHASE3)
- MEDITOXIN® Versus BOTOX® in the Treatment of Post-stroke Spasticity of the Upper Limb Spasticity (PHASE3)
- Meditoxin® Treatment in Patients With Post Stroke Upper Limb Spasticity (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Meditoxin CI brief — competitive landscape report
- Meditoxin updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI